Vertical Soft Tissue Augmentation With CTG vs ADM
ConditionImplant Complication
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-99
SponsorHarvard Medical School (HMS and HSDM)
About this trial
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative
Eligibility criteria
Qualifiers
Age ≥ 18 years
Periodontally and systemically healthy
Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)
Presence of single functional dental implant in the anterior with a PSTD
Disqualifiers
Contraindications for surgery
Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing
Patients pregnant or attempting to get pregnant (self-reported)
Untreated periodontitis
Trial design
Treatments tested in this trial
- Vertical soft tissue augmentation
- Vertical soft tissue augmentation
Treatment groups
28 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov